The explainer library. Zero filler.
Every article below runs 1,500+ words, cites the primary trials by name, flags what we could not verify, and links the ledger where money is involved. Sixty percent lean tirzepatide, forty semaglutide — matching where the market's questions actually are. Medical review is pending and honestly labeled; citations should be checked against PubMed and FDA sources before external use.
Start here: the statistics file · the 27-trial index · how to read a study · the side-effect tables · the true-cost method · the coverage playbook
ComparisonsTirzepatide vs Semaglutide: The Head-to-Head Verdict
SURMOUNT-5 settled the average — 20.2% vs 13.7% — but the right molecule is chosen by profile, not leaderboard.
CostsThe True Cost of GLP-1 Therapy
Teaser rates, dose ladders, fee stacks — and the worked math that turns any pricing page into a 12-month all-in number.
RegulationCompounded GLP-1s in 2026: The Legal Status, Plainly
The shortage-era timeline, where the 503A/503B lines sit now, and the six-question checklist before you buy.
SafetyGLP-1 Side Effects: What the Trials Actually Show
Base rates from the pivotal programs, the titration-week timeline, the management playbook, and the symptoms that skip the tips.
Evidence checkDo Tirzepatide Tablets Work?
No FDA-approved oral tirzepatide exists — the bioavailability problem, the ODT evidence gap, and five questions that test any oral claim.
Trend vs trialsMicrodosing GLP-1s: What Low Doses Actually Do
The dose-response curves, the three legitimate kernels inside the trend, and where the evidence map simply ends.
Body compositionKeeping Muscle on Tirzepatide
The lean-mass substudies, the protein numbers, the two-day lifting week, and the muscle-sparing drugs in the pipeline.
IndicationsZepbound for Sleep Apnea: The First Drug Approval for OSA
SURMOUNT-OSA cut ~20 events/hour vs placebo — who fits the label, and the Medicare door the indication opens.
OutcomesSemaglutide and the Heart: What SELECT Changed
A 20% MACE reduction in 17,604 people without diabetes — absolute numbers, safety at scale, and how it steers molecule choice.
PipelineThe Oral GLP-1 Pipeline, Honestly Timed
Orforglipron, 25 mg oral semaglutide, amycretin — the chemistry, the phase-3 numbers, and what it means for the tablet gray market.
PipelineRetatrutide: The Triple Agonist, Previewed Responsibly
~24% in phase 2 and a liver signal hepatologists noticed — plus why phase-2 numbers shrink and who should not wait.
MaintenanceComing Off a GLP-1: Taper, Maintenance, and the Regain Data
STEP 1 extension and SURMOUNT-4 quantified stopping. The physiology, an illustrative taper, and the eight-question exit template.
Emerging evidenceGLP-1s and Alcohol: The Craving Signal
From clinic anecdote to a 2025 randomized trial — the reward-circuit mechanism, three evidence tiers, and the line before treatment.
CoverageGLP-1 Insurance in 2026: Formulary Wars and Medicare Doors
The PBM that picked Wegovy over Zepbound, indication-shaped Medicare routes, and the exception letter that actually wins.
TroubleshootingThe GLP-1 Plateau: The Evidence-Ordered Response Ladder
Why every trial curve flattens on schedule, the fake plateaus to rule out first, and the rung where the plateau is the destination.
Organ outcomesBeyond the Scale: MASH, Kidneys, and the Organ Evidence
ESSENCE and FLOW earned new indications — the decision rule when a diagnosis, not the scale, picks your molecule.
Consumer protectionThe Gray Market in GLP-1 Peptides: Why We Refuse to Price It
What testing finds in research-use vials, why the savings math collapses, and every cheaper legitimate lane that exists.
MechanismsFood Noise: The Neuroscience Behind the Patient Phrase
The two-channel brain, how GLP-1s reach the reward dial, when quiet overshoots, and why the volume returns off-drug.
SafetyGLP-1s, Fertility, and Pregnancy: What “Ozempic Babies” Actually Are
Restored ovulation, the tirzepatide birth-control interaction written into the label, the two-month semaglutide washout, and what early human data shows.
SafetyThe Thyroid Boxed Warning, Explained
Rodent C-cells, the conflicting human cohorts, the narrow MTC/MEN 2 contraindication, and why routine calcitonin screening isn’t recommended.
PracticalSwitching From Compounded to Brand
Dose mapping, gap-and-restart rules, LillyDirect and NovoCare mechanics, device-change safety, and the honest 12-month money math.
PracticalVials, Pens, and Syringes: The Device Guide
Four delivery systems, the FDA-documented unit-math errors, how to read a compounded label, and the checklist for every device change.
PracticalManaging GLP-1 Nausea
The trial base rates, the three levers — titration pace, mechanical eating, scheduled hydration — antiemetic realities, and the red flags.
SafetyGallbladder Disease and Pancreatitis
The risk the trials confirm, the one they mostly don’t, both symptom scripts, and the monitoring that’s evidence-aligned versus theater.
MoneyThe Anatomy of a $99 Teaser
Five pricing moves that turn an advertised month into a $3,000 year — with the worked example and the six questions that defeat them.
SafetyGLP-1s and Mental Health: The Evidence
The 2023 scare, the FDA and EMA conclusions, the cohort data trending favorable, and starting therapy with a psychiatric history.
PracticalHair Shedding: Telogen Effluvium Explained
The trial rates, the follicle-cycle mechanism, the 2–4 month lag and recovery arc, the protein and ferritin levers, and the imposters.
PracticalThe Protein-First Nutrition Playbook
Eating on a suppressed appetite: the 1.2–1.6 g/kg logic, fiber and fluid mechanics, screen-worthy micronutrients, and a workable day.
Practical“Ozempic Face” and Loose Skin
What rapid fat loss actually does to appearance, the age variable, the levers that help, and how to price procedures with honest physics.
Safety fileGLP-1 drug interactions: the label-level guide
Levothyroxine, warfarin, insulin stacking, tirzepatide’s birth-control rule, and the one mechanism behind all of it.
Safety fileGLP-1s with GERD or gastroparesis
Who should be careful, what the ileus label addition means, and when a different tool is the honest answer.
Practical fileStoring and traveling with GLP-1s
Room-temperature windows by product, flying rules, hotel-fridge ambushes, and time-zone math for weekly doses.
Consumer defenseIs that online pharmacy legitimate?
The eight-step verification checklist — licenses, LegitScript, COAs, payment red flags — anyone can run tonight.
EvidenceGLP-1s for PCOS: The Evidence Review
The insulin-resistance logic, the small trials, the 2023 international guideline’s narrow sanction, and the restored-ovulation surprise the marketing omits.
EvidenceBariatric Surgery vs. GLP-1s
Magnitude, durability, risk ledgers, and ten-year money — the honest head-to-head from a drug-side site, combination era included.
MoneyCost per Pound Lost, Computed Honestly
$50–$643 per pound depending on channel — the worked math on verified figures, and the four ways the metric lies.
EvidenceGLP-1s for Teenagers: The Family File
STEP TEENS, the AAP guideline, the legitimate unknowns, and why the venue — pediatric clinic, never DTC — matters more than the molecule.
Evidence fileGLP-1s after 65: the older-adult file
Muscle as currency, the dehydration-falls window, deprescribing wins, and the Medicare map by indication.
ExplainerMounjaro vs Zepbound: same drug, two labels
Identical tirzepatide — and why the name on the pen decides your coverage and your cash channel.
ExplainerWegovy vs Ozempic: same drug, two labels
One semaglutide, different doses and doors — including the SELECT indication that reopened Medicare.
Practical fileThe GLP-1 constipation file
Slower, smaller, drier: the mechanism and the OTC ladder — plus the red-flag cluster that means stop.
Practical fileInjection technique: pens, vials, and the mistakes that matter
Sites, rotation, pen mechanics — and the compounded-vial concentration trap behind real overdoses.
Clinical fileLabs on a GLP-1: what to check, what to skip
The baseline panel, interaction-driven rechecks, symptom-triggered tests — and the screening the labels decline.
PlaybookAppealing a GLP-1 denial: the letter that works
Decode the denial code, stack dated exhibits, mirror the label, and escalate to external review — template included.
Diligence fileHow to read a CoA before you inject anything
Lot match, assay vs label, sterility and endotoxin, 503A vs 503B — and the forgery-aware limits of paperwork.
Practical fileTaste changes and food aversions
Metallic coffee, cardboard chicken: what’s documented, the likely mechanisms, and the cold-acid-texture workarounds.
Practical fileHeadaches, dizziness, fatigue
The four fixable causes — fuel, fluid, BP-med overshoot, caffeine — plus the one to rule out first.
Practical fileRestaurants, holidays, and hosts
Order for the appetite you have, three polite scripts, alcohol’s new math, and firing the clean-plate voice.
Evidence fileSemaglutide vs liraglutide: STEP 8
The rare same-trial head-to-head: ~16% vs ~6% — and the three niches where the older daily drug survives.
Evidence fileThe heart-rate file: why your pulse crept up
The labeled few-beat bump, wearable-era monitoring without spiraling, and the red flags that exit the file.
Clinical fileHydration, electrolytes, and your kidneys
Why the class dehydrates by design, the AKI pathway, sick-day rules — and the FLOW paradox resolved.
Practical fileTraining on a GLP-1: the programming file
Resistance first, cardio placed right, session fueling, and deloads timed to your titration calendar.
Evidence fileGLP-1s and menopause: the careful file
What the trials quietly proved, the HRT non-interaction, and the doubled muscle-bone stakes — hedged where thin.
Practical fileShift work on a GLP-1
Calendar-anchored shots, night-eating architecture, hydration on the night side, and the label windows that forgive.
Practical fileDry mouth, enamel, and the dentist
The mouth’s quiet tolls — dryness, acid events — and the two-habit protocol that retires them.
Data fileGLP-1 by the numbers: 2026 statistics
Usage, spending, discontinuation, trial-by-trial efficacy, prices — every figure source-named, dated, and hedged.
AnalysisEight trends reshaping GLP-1s through 2027
Pills at scale, indication accretion, price compression, muscle co-therapies — forecasts with tripwires attached.
Data fileThe GLP-1 trial index
Twenty-seven pivotal studies in one sourced table — the citation backbone of the entire library, mirrored in JSON.
Method fileHow to read a GLP-1 study
Endpoints, placebo math, estimands, withdrawal designs, spin patterns — and the ten-point checklist to audit any claim.
SafetyGLP-1s, Anesthesia, and Surgery Day
The full-stomach problem, how guidance matured from blanket holds to individualized protocols, and the pre-op script to read aloud.
Cheapest Compounded Tirzepatide Online: The Prose LedgerCosts
The verified price floor stated entirely in words — six checks, three teaser patterns, and a twelve-month narrative of what cheap really means.
Next in the pipeline
Briefs drafted, publication paced at roughly two per month so verification keeps up with volume — the anti-content-farm schedule our methodology commits to.
- GLP-1s in adolescents: what the pediatric trials actually enrolled brief drafted
- Thyroid warnings decoded: rodents, humans, and the registry data brief drafted
- GLP-1s and mental health: the signal-vs-noise file brief drafted
- Bariatric surgery vs pharmacotherapy in 2026: the honest comparison brief drafted
- Semaglutide and osteoarthritis: weight, knees, and the STEP 9 evidence brief drafted
- Travel, storage, and cold chains: the practical handling guide brief drafted
- Fertility, pregnancy timing, and GLP-1s: what the labels require brief drafted
- The CagriSema file: amylin combinations after REDEFINE brief drafted